Fulcrum Therapeutics Inc (FULC) with a beta value of 2.25 appears to be a promising investment opportunity.

A new trading day began on Monday, with Fulcrum Therapeutics Inc (NASDAQ: FULC) stock price up 4.52% from the previous day of trading, before settling in for the closing price of $8.85. FULC’s price has ranged from $2.25 to $13.22 over the past 52 weeks.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Healthcare Sector giant saw their annual sales surged by 12.57% over the last five years. Meanwhile, its annual earnings per share averaged 32.79%. With a float of $58.65 million, this company’s outstanding shares have now reached $61.82 million.

Fulcrum Therapeutics Inc (FULC) Breakdown of a Key Holders of the stock

As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Fulcrum Therapeutics Inc is 5.14%, while institutional ownership is 79.63%. The most recent insider transaction that took place on May 10, was worth 695. In this transaction Principal Accounting Officer of this company sold 210 shares at a rate of $3.31, taking the stock ownership to the 15,992 shares.

Fulcrum Therapeutics Inc (FULC) Recent Fiscal highlights

Wall Street market experts anticipate that the next fiscal year will bring earnings of 68.18 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 32.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.40% during the next five years compared to -17.57% drop over the previous five years of trading.

Fulcrum Therapeutics Inc (NASDAQ: FULC) Trading Performance Indicators

Here are Fulcrum Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 18.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 218.26.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.69, a number that is poised to hit -0.43 in the next quarter and is forecasted to reach -1.79 in one year’s time.

Technical Analysis of Fulcrum Therapeutics Inc (FULC)

Analysing the last 5-days average volume posted by the [Fulcrum Therapeutics Inc, FULC], we can find that recorded value of 0.6 million was lower than the volume posted last year of 0.61 million. As of the previous 9 days, the stock’s Stochastic %D was 89.89%. Additionally, its Average True Range was 0.53.

During the past 100 days, Fulcrum Therapeutics Inc’s (FULC) raw stochastic average was set at 97.76%, which indicates a significant increase from 94.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.86% in the past 14 days, which was lower than the 88.69% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $6.66, while its 200-day Moving Average is $4.56. Now, the first resistance to watch is $9.55. This is followed by the second major resistance level at $9.86. The third major resistance level sits at $10.32. If the price goes on to break the first support level at $8.78, it is likely to go to the next support level at $8.32. Now, if the price goes above the second support level, the third support stands at $8.01.

Fulcrum Therapeutics Inc (NASDAQ: FULC) Key Stats

With a market capitalization of 571.84 million, the company has a total of 61,823K Shares Outstanding. Currently, annual sales are 6,340 K while annual income is -109,870 K. The company’s previous quarter sales were 760 K while its latest quarter income was -24,020 K.